How have BCTXF shares performed in 2024?

BriaCell Therapeutics' stock was trading at $5.85 at the beginning of 2024. Since then, BCTXF shares have decreased by 60.3% and is now trading at $2.32. View the best growth stocks for 2024 here .

How do I buy shares of BriaCell Therapeutics?

Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:BCTXF

BriaCell Therapeutics (BCTXF) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free BCTXF Stock Alerts

$2.32

-0.17 (-6.83%)

(As of 04/15/2024 ET)

Compare

Today's Range: $2.30
▼
$2.56
50-Day Range: $2.24
▼
$4.14
52-Week Range: $3.25
▼
$17.50

Volume: 35,541 shs
Average Volume: 1,859 shs
Market Capitalization: $1.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines

Get BriaCell Therapeutics alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About BriaCell Therapeutics Stock (OTCMKTS:BCTXF)

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BCTXF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCTXF Stock News Headlines

February 2, 2024 | msn.com

BriaCell’s Shareholders Approve Directors and Auditors

January 4, 2024 | finanznachrichten.de

BriaCell Therapeutics Corp.: BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer

April 15, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

November 15, 2023 | businesswire.com

MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

October 25, 2023 | finance.yahoo.com

BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

October 20, 2023 | finance.yahoo.com

October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology

September 26, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp flat on Monday (BCT)

September 10, 2023 | msn.com

BriaCell Therapeutics: Poised To Move To Advanced Trials, But An Unconvincing Thesis

April 15, 2024 | American Alternative (Ad)

Your Money is Not Safe

September 8, 2023 | finance.yahoo.com

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

August 18, 2023 | finance.yahoo.com

BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting

August 17, 2023 | msn.com

BriaCell receives NCI grant for cancer platform development

July 22, 2023 | theglobeandmail.com

BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT)

June 28, 2023 | markets.businessinsider.com

BriaCell Therapeutics (BCT) Gets a Buy Rating from H.C. Wainwright

May 25, 2023 | marketwatch.com

BriaCell Therapeutics in Definitive Agreement to Spin Off Certain Assets

May 25, 2023 | msn.com

BriaCell to spin out BriaPro Therapeutics

April 27, 2023 | theglobeandmail.com

BriaCell Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (BCT)

April 7, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp down on Thursday (BCT)

April 1, 2023 | morningstar.com

Toronto Stocks Advance as Banking Sector Sentiment Improves; BriaCell Slides on Spinoff Plans

March 30, 2023 | marketwatch.com

BriaCell Therapeutics to Spin Off Certain Assets

February 23, 2023 | marketwatch.com

BriaCell Sees Positive Survival Data in Ongoing Trial

February 23, 2023 | finance.yahoo.com

BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer

January 23, 2023 | marketwatch.com

BriaCell to Investigate Potential Stock Manipulation

January 12, 2023 | stockhouse.com

BriaCell Announces New Patent Issuance, Bria-OTS(TM) IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

January 10, 2023 | msn.com

BriaCell to get US, Australian patent linked to personalized cancer immunotherapy

August 5, 2022 | bizjournals.com

BriaCell signs exclusive licensing deal with UMBC for cancer treatment candidate

July 21, 2022 | finance.yahoo.com

BriaCell Therapeutics Corp. (TSE:BCT) insider upped their holding earlier this year

See More Headlines

Receive BCTXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:BCTXF
CUSIP: N/A
CIK: N/A
Web: www.briacell.com
Phone: (604) 921-1810
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,680,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -786.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.07
Quick Ratio: 0.07

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.55) per share
Price / Book: -0.55

Miscellaneous

Outstanding Shares: 772,000
Free Float: N/A
Market Cap: $1.92 million
Optionable: Not Optionable
Beta: 1.09

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

William V. Williams
President, Chief Executive Officer & Director
Gadi Levin
Chief Financial Officer & Secretary
Farrah Dean
Manager-Corporate Development & IR Contact

Key Competitors

View All Competitors

BCTXF Stock Analysis - Frequently Asked Questions

How have BCTXF shares performed in 2024?: BriaCell Therapeutics' stock was trading at $5.85 at the beginning of 2024. Since then, BCTXF shares have decreased by 60.3% and is now trading at $2.32.
View the best growth stocks for 2024 here.
How do I buy shares of BriaCell Therapeutics?: Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BCTXF) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial